AEGERION PHARMACEUTICALS
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.
AEGERION PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.aegerion.com
Total Employee:
101+
Status:
Active
Contact:
(855) 305-2347
Total Funding:
63.68 M USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt Amazon HSTS Linode SMTP2GO
Similar Organizations
Antlia Bioscience
Antlia Bioscience develops peptide-based therapies to treat cardiovascular and metabolic diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cequent Pharmaceuticals
Cequent is a biopharmaceutical company pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases.
Energesis Pharmaceuticals
Energesis Pharmaceuticals focuses on the discovery and development of drugs to treat obesity, diabetes, and related metabolic diseases.
EyeCyte
EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Rinat Neuroscience
A leader in the development of therapeutic antibodies, spun out its key neuroscience assets under a broad license to Rinat.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Antonio M. Gotto Jr Weill Medical College of Cornell University @ Aegerion Pharmaceuticals
Weill Medical College of Cornell University
David Allmond President, EMEA @ Aegerion Pharmaceuticals
President, EMEA
2015-07-01
Mary Szela Chief Executive Officer @ Aegerion Pharmaceuticals
Chief Executive Officer
2016-01-01
Melissa Morandi Vice President Global Quality @ Aegerion Pharmaceuticals
Vice President Global Quality
2015-04-01
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-11-06 | Myalept | Myalept acquired by Aegerion Pharmaceuticals | N/A |
Investors List
Alta Partners
Alta Partners investment in Convertible Note - Aegerion Pharmaceuticals
Scheer Partners Investments
Scheer Partners Investments investment in Convertible Note - Aegerion Pharmaceuticals
Index Ventures
Index Ventures investment in Convertible Note - Aegerion Pharmaceuticals
Advent International
Advent International investment in Convertible Note - Aegerion Pharmaceuticals
Alta Partners
Alta Partners investment in Series B - Aegerion Pharmaceuticals
Index Ventures
Index Ventures investment in Series B - Aegerion Pharmaceuticals
Advent International
Advent International investment in Series B - Aegerion Pharmaceuticals
Scheer Partners Investments
Scheer Partners Investments investment in Series B - Aegerion Pharmaceuticals
Advent International
Advent International investment in Series A - Aegerion Pharmaceuticals
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Aegerion Pharmaceuticals
Official Site Inspections
http://www.aegerion.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aegerion Pharmaceuticals"
Aegerion Pharmaceuticals - Crunchbase Company …
Aegerion Pharmaceuticals closed its last funding round on Oct 11, 2010 from a Venture - Series Unknown round. Who are Aegerion Pharmaceuticals 's competitors? Alternatives and possible competitors to Aegerion …See details»
Aegerion Pharmaceuticals - Funding, Financials, Valuation
Nov 6, 2014 Aegerion Pharmaceuticals is registered under the ticker NASDAQ:AEGR . Their stock opened with $9.50 in its Oct 22, 2010 IPO. Aegerion Pharmaceuticals is funded by 5 …See details»
Aegerion Pharmaceuticals Overview | SignalHire Company Profile
Its headquarters is located at London, England, GB. The number of employees ranges from 100 to 250. The annual revenue of Aegerion Pharmaceuticals varies between 100M and 500M. …See details»
Aegerion Pharmaceuticals - PitchBook
Aegerion Pharmaceuticals was acquired on 24-Sep-2019. Who acquired Aegerion Pharmaceuticals? Aegerion Pharmaceuticals was acquired by Amryt Pharma. Data …See details»
Aegerion Pharmaceuticals Holdings, Inc - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Aegerion Pharmaceuticals Holdings, Inc of Cambridge, MA. Get the latest business insights from Dun & …See details»
Aegerion Pharmaceuticals - Updates, News, Events, Signals
Jun 25, 2024 Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases. Search Crunchbase. Start …See details»
Press Release - SEC.gov
“2012 was a year of significant accomplishments for Aegerion culminating with the FDA approval of JUXTAPID in December,” said Marc Beer, Chief Executive Officer of Aegerion. “We expect …See details»
Aegerion Pharmaceuticals | EquityNet
Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. Marc …See details»
Aegerion Pharmaceuticals - Overview, News & Similar companies ...
You are leaving the Aegerion Pharmaceuticals, Inc. website. Do you wish to continue? Read more. Is this data correct? Popular Searches Aegerion Pharmaceuticals Inc SIC Code 28,283 …See details»
Aegerion Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Explore Aegerion Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 23 clinical trials, 31 news, and 18 literature, Drug:AEG-41174, Lomitapide Mesylate, …See details»
www.aegerion.com
Www.aegerion.comSee details»
Aegerion Pharmaceuticals - Overview, News & Similar ... - ZoomInfo
Aegerion Pharmaceuticals is a company that operates in the Pharmaceuticals industry. It employs 6-10 people and has $1M-$5M of revenue. The company is headquartered in Uxbridge, …See details»
Orphanet: AEGERION PHARMACEUTICALS, INC.
Aegerion Pharmaceuticals Inc. Aegerion Pharmaceuticals Inc. 101 Main Street, Suite 1850 CAMBRIDGE MA 02142 UNITED STATES. Phone 1: 1 855 305 2347. Contact email: …See details»
Aegerion - Company Profile - Tracxn
Nov 17, 2024 Aegerion Pharmaceuticals is a biopharmaceutical company that develops pharmaceuticals to treat cardiovascular and metabolic diseases. Products include Juxtapid as …See details»
Amryt buys Aegerion via bankruptcy, adding sales to support R&D
Sep 25, 2019 The deal, which comes after Aegerion filed for Chapter 11 bankruptcy, gives Amryt near-full control of two commercial drugs that could provide revenues to support its protracted …See details»
Aegerion Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Aegerion Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Number of Board Member and Advisor Profiles 4. Contacts 8. …See details»
Marc Beer, Founder and Chairman | LumeNXT
Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease. ... and over a period of seven years led …See details»
Aegerion Pharmaceuticals - CB Insights
Alison joined Alta Partners as an Associate in 2001 and became a Director of Alta Partners VIII in 2006. Her primary investment focus at Alta is on medical technology and biopharmaceuticals. …See details»
Aegerion Pharmaceuticals - Overview, News & Similar companies ...
View Aegerion Pharmaceuticals (www.aegerionsecuritieslitigation.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Office of Public Affairs | Drug Maker Aegerion Agrees to Plead …
Sep 22, 2017 The government further alleged that Aegerion defrayed patients’ copayment obligations for Juxtapid, in violation of the Anti-Kickback Statute (AKS), by funneling funds …See details»